NCT00106366已完成3 期
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 389
- 试验地点
- 79
- 主要终点
- HbA1c
研究概览
简要总结
This trial is conducted in the United States of America (USA). The purpose of this study is to determine if the use of insulin detemir in combination with insulin aspart is safe and at least as effective as insulin glargine in combination with insulin aspart for the control of blood glucose in patients with Type 2 diabetes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Type 2 Diabetes for more than 12 months
- •Currently treated with glucose lowering tablets or insulin
- •HbA1c: 7.0-12.0%
排除标准
- 未提供
结局指标
主要结局
HbA1c
时间窗: after 26 weeks
次要结局
- Body weight
- Glucose profiles
研究者
研究点 (79)
Loading locations...
相似试验
已完成
3 期
Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT00104182Novo Nordisk A/S503
已完成
3 期
Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT00097084Novo Nordisk A/S324
已完成
3 期
Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 DiabetesDiabetesDiabetes Mellitus, Type 1NCT00095082Novo Nordisk A/S447
已完成
3 期
Efficacy and Safety of Insulin Detemir in Type 1 DiabetesDiabetesDiabetes Mellitus, Type 1NCT00595374Novo Nordisk A/S114
已完成
3 期
The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT00856986Novo Nordisk A/S987